Park City Angels

iVeena is a biopharmaceutical company focused on developing innovative treatments for ophthalmic diseases. Founded in 2006 by Bala Ambati and headquartered in Salt Lake City, Utah, iVeena is advancing five products that are currently in late pre-clinical and research stages. The company's targeted indications include post-surgery cataract inflammation, macular degeneration (Wet AMD), diabetic retinopathy, and glaucoma. iVeena utilizes proprietary drug delivery systems, including methods that allow for treatment directly from the lens capsule, which enhances the effectiveness of therapies for corneal diseases and myopic conditions.

iVeena is a biopharmaceutical company focused on developing innovative treatments for ophthalmic diseases. Founded in 2006 by Bala Ambati and headquartered in Salt Lake City, Utah, iVeena is advancing five products that are currently in late pre-clinical and research stages. The company's targeted indications include post-surgery cataract inflammation, macular degeneration (Wet AMD), diabetic retinopathy, and glaucoma. iVeena utilizes proprietary drug delivery systems, including methods that allow for treatment directly from the lens capsule, which enhances the effectiveness of therapies for corneal diseases and myopic conditions.

Veristride, Inc. is a company based in South Salt Lake, Utah, specializing in shoe-based sensor technology designed to analyze human movement. Founded in 2011, Veristride develops sensors integrated into shoe insoles that provide users with real-time feedback on their walking, running, and overall movement patterns. This technology allows individuals to monitor their movement abilities and track injuries, promoting wellness and enabling users to achieve their health and performance goals through data-backed analytics. By focusing on movement at the source, Veristride aims to support users in their recovery and performance enhancement journeys.

Tute Genomics is a cloud-based clinical genome interpretation platform based in Provo, Utah, founded in 2012. The company specializes in providing advanced analytical methods for genome analysis, utilizing proprietary machine-learning algorithms to facilitate the analysis and interpretation of entire human genomes. By enabling researchers and clinicians to leverage human genome data, Tute Genomics supports scientific discovery and the development of personalized treatment options. Its platform is designed to help physicians identify genes and biomarkers, ultimately advancing personalized medicine in the life sciences sector.